BFM
TENX icon

Boothbay Fund Management’s Tenax Therapeutics TENX Stock Holding History

Boothbay Fund Management’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
111,100
+78,000
+236% +$996K 0.02% 825
2026
Q1 		$529K Buy
+33,100
New +$448K 0.01% 1312

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Boothbay Fund Management's TENX Position: Q2 2026 in Review

Boothbay Fund Management reduced its Tenax Therapeutics (TENX) stake by 15% in Q2 2026, selling an estimated $712K and leaving 311,087 shares worth $4.53M. The position accounts for 0.06% of the portfolio, ranked #383.

Boothbay Fund Management first reported a position in TENX in Q3 2021 and has held it in 7 quarters since. The position peaked at $5.86M in Q1 2026. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Boothbay Fund Management held 311,087 shares of Tenax Therapeutics worth $4.53M as of Q2 2026.
  • Boothbay Fund Management sold 55,704 Tenax Therapeutics shares in Q2 2026, an estimated $712K.
  • Tenax Therapeutics made up 0.06% of Boothbay Fund Management's portfolio in Q2 2026, its #383 holding.
  • Boothbay Fund Management first reported a position in Tenax Therapeutics in Q3 2021 and has held it in 7 quarters since.
  • Boothbay Fund Management's Tenax Therapeutics position peaked at $5.86M in Q1 2026.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.